Roth Capital Reiterates Buy On Cytori Therapeutics, $3.50 PT
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Cytori Therapeutics (NASDAQ:CYTX) with a price target of $3.50, which represents a potential upside of 614% from where the stock is currently trading.
Pantginis noted, “Cytori announced 3Q14 results, provided an in depth update on their clinical programs as well as outlining the revamped corporate strategy going forward. To this end, the company is being very selective in what therapeutic indications it is bringing forward, being proactive with potential partners, and significantly managing expenses. With an effective reboot underway, we maintain our Buy rating.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -6.1% and a 41.4% success rate. Pantginis has a -73.1% average return when recommending CYTX, and is ranked #3306 out of 3364 analysts.